Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or ...

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...

The CATALYST meta-analysis pooled the four studies and identified 5,441 people with acute ischemic stroke and Afib for inclusion. The population largely came from OPTIMAS (67%), followed by the TIMING ...

Valo Health is growing its workforce as the Boston-area biotech expands to meet the needs of its partnerships, including a ...

Novo Nordisk is under fire over a Spanish obesity awareness campaign. | Novo Nordisk is under fire over a Spanish obesity ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...